Abstract
Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo. In vitro studies indicate that retapamulin has a unique mode of action that minimizes the potential for target-specific cross-resistance with other antibacterials and a limited potential for resistance development. Its spectrum of activity includes the most likely causative pathogens Staphylococcus aureus and Streptococcus pyogenes. In the Global Surveillance Program, retapamulin was highly active in vitro, including against strains of S. aureus resistant to methicillin, mupirocin or fusidic acid. In clinical studies, retapamulin was noninferior to fusidic acid and oral cefalexin, achieving per-pathogen success rates of 86-99%. Topical retapamulin has a good safety profile and is associated with high patient compliance.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Administration, Cutaneous
-
Anti-Bacterial Agents* / administration & dosage
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
-
Bridged Bicyclo Compounds, Heterocyclic* / pharmacology
-
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
-
Diterpenes
-
Drug Resistance, Bacterial
-
Global Health
-
Humans
-
Microbial Sensitivity Tests
-
Ointments / administration & dosage
-
Population Surveillance / methods
-
Skin Diseases, Bacterial / drug therapy*
-
Skin Diseases, Bacterial / microbiology*
-
Staphylococcal Skin Infections / drug therapy
-
Staphylococcal Skin Infections / microbiology
-
Staphylococcus aureus / drug effects
-
Streptococcal Infections / drug therapy
-
Streptococcal Infections / microbiology
-
Streptococcus pyogenes / drug effects
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Bridged Bicyclo Compounds, Heterocyclic
-
Diterpenes
-
Ointments
-
retapamulin